#CardioMindSync - Twitter Hashtag

4 days ago

DAN-RSV RSVpreF vaccination reduced RSV-related hospitalization by ~70% in a pragmatic trial of 511,535 adults. Serious events were similar, but 5 Guillain–Barré cases vs 0 support continued surveillance. #ESC2026 #DANRSV #CardioMindSync

Mohamme76294268's tweet photo. DAN-RSV

RSVpreF vaccination reduced RSV-related hospitalization by ~70% in a pragmatic trial of 511,535 adults. Serious events were similar, but 5 Guillain–Barré cases vs 0 support continued surveillance.

#ESC2026 #DANRSV #CardioMindSync https://t.co/8VZJd1EprA

0

34

Mohammed Al-Qadami @Mohamme76294268

4 days ago

After intracranial hemorrhage in AF, edoxaban reduced ischemic stroke by 43% but nearly doubled major bleeding (11.6% vs 5.2%), with no net clinical benefit. Findings support individualized—not routine—use. #ESC2026 #ENRICHAF #CardioMindSync

Mohamme76294268's tweet photo. After intracranial hemorrhage in AF, edoxaban reduced ischemic stroke by 43% but nearly doubled major bleeding (11.6% vs 5.2%), with no net clinical benefit. Findings support individualized—not routine—use.
#ESC2026 #ENRICHAF #CardioMindSync https://t.co/i6P931i2SM

0

82

Mohammed Al-Qadami @Mohamme76294268

4 days ago

Silent atherosclerosis starts early—around age 40 it was present in ~50% of men and ~30% of women, rising from 1 in 13 in the youngest to 9 in 10 in the oldest. Observational data do not yet prove benefit from screening. #ESC2026 #REACT #CardioMindSync

Mohamme76294268's tweet photo. Silent atherosclerosis starts early—around age 40 it was present in ~50% of men and ~30% of women, rising from 1 in 13 in the youngest to 9 in 10 in the oldest. Observational data do not yet prove benefit from screening.

#ESC2026 #REACT #CardioMindSync https://t.co/2vNUlxgIhK

0

48

Mohammed Al-Qadami @Mohamme76294268

4 days ago

In stage 3–4 CKD, pacibekitug reduced hsCRP by 75–86%, sustained through day 180, with no emerging safety signal. Promising anti-inflammatory proof of concept; larger outcome trials are still needed. #ESC2026 #RANQUILITY #CardioMindSync

Mohamme76294268's tweet photo. In stage 3–4 CKD, pacibekitug reduced hsCRP by 75–86%, sustained through day 180, with no emerging safety signal. Promising anti-inflammatory proof of concept; larger outcome trials are still needed.

#ESC2026 #RANQUILITY #CardioMindSync https://t.co/MHESYxiZhA

0

50

Mohammed Al-Qadami @Mohamme76294268

4 days ago

tarting evolocumab before PCI increased LDL-C target attainment to 82% vs 40%, but did not reduce death or unplanned CV hospitalization at 1 year. Strong lipid effect without early clinical benefit. #ESC2026 #AMUNDSEN #CardioMindSync

Mohamme76294268's tweet photo. tarting evolocumab before PCI increased LDL-C target attainment to 82% vs 40%, but did not reduce death or unplanned CV hospitalization at 1 year. Strong lipid effect without early clinical benefit.

#ESC2026 #AMUNDSEN #CardioMindSync https://t.co/diR8hAl9c3

0

1

0

69

Mohammed Al-Qadami @Mohamme76294268

4 days ago

In adults ≥70 without known CVD, atorvastatin 40 mg reduced major CV events (6.0% vs 8.3%; HR 0.70) but did not improve disability-free survival. Clear CV benefit, with treatment individualized to risk and preference. #ESC2026 #STAREE #CardioMindSync

Mohamme76294268's tweet photo. In adults ≥70 without known CVD, atorvastatin 40 mg reduced major CV events (6.0% vs 8.3%; HR 0.70) but did not improve disability-free survival. Clear CV benefit, with treatment individualized to risk and preference.

#ESC2026 #STAREE #CardioMindSync https://t.co/EOZNIbvzHS

0

73

Top Tweets for #CardioMindSync

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users